Predictors of Local Recurrence after Radiofrequency Ablation of Liver Tumors. by Rajarathinam, G
 DISSERTATION ON PREDICTORS  
OF LOCAL RECURRENCE AFTER RADIOFREQUENCY ABLATION OF 
LIVER TUMORS  
Dissertation  
Submitted in partial fulfillment of the Regulation of  
M. Ch. DEGREE EXAMINATION  
BRANCH VI IN SURGICAL GASTROENTEROLOGY, 
 
INSTITUTE OF SURGICAL GASTROENTEROLOGY 
GOVT. STANLEY MEDICAL COLLEGE &HOSPITAL,  
Chennai – 600 001 
 
 
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY  
CHENNAI  
AUGUST 2008 
 
  
                                  DECLARATION 
 
  I, Dr.G.Rajarathinam, solemnly declare that  
 
dissertation titled, “Predictors of Local Recurrence After 
Radiofrequency Ablation of Liver Tumors  " is the bonafide work 
done by me at Govt. Stanley Medical College and Hospital during 
the period  September  2005 to February 2008 under the expert 
guidance and supervision of  Prof. R. Surendran, M.S., 
M.N.A.M.S.,M.Ch. Head of the Department, Institute of Surgical 
Gastroenterology. 
 The dissertation is submitted to the Tamil Nadu  
Dr. MGR Medical University towards partial fulfillment of 
requirement for the award of M.Ch Degree (Branch VI) in Surgical 
Gastroenterology. 
Dr. G.Rajarathinam 
Place : Chennai       
Date : 21.05.08                . 
  
CERTIFICATE 
 
 This is to certify that this dissertation entitled " Predictors of 
Local Recurrence After Radiofrequency Ablation of Liver 
Tumors " is a bonafide original work of  Dr.G.Rajarathinam in 
partial fulfillment of the requirement for M.Ch (Branch VI) Surgical 
Gastroenterology examination of the  Tamil Nadu Dr.MGR 
Medical University to be held in August 2008 
.  
 
 
 
 
Place: Chennai 
Date : 29.05.08 
Dr.A. Sundaram, MD., 
Dean  (I/c) 
Govt. Stanley Medical College and 
Hospital 
Chennai - 1. 
Prof.R.Surendran, M.S.,MNAMS.,M.Ch., 
Head of the Department 
Institute of surgical Gastroenterology 
Govt.Stanley Medical college&Hospital 
Chennai-1 
 ACKNOWLEDGMENT 
 
 
          I profusely thank Dr. Sundaram MD., Dean, Govt. Stanley Medical college, 
Chennai, who permitted to pursue research work and to utilize the case material. 
I express my sincere gratitude to my chief, Prof.R.Surendran, 
M.S.,M.N.A.M.S.,M.Ch. Head of the Department, Department of Surgical 
Gastroenterology, Chennai for his keen interest, constant encouragement, guidance 
and valuable suggestions throughout this study. 
 
 I am extremely thankful to my Assistant Professors  Dr.S.Jeswanth, 
M.S.,M.Ch,  Dr.P.Ravichandran,M.S,M.Ch, Dr.V.Vimalraj,M.S,M.Ch, 
Dr.S.RajendranM.S.,M.Ch, Dr.D.Jothybasu,MS, Dr.Sukumar,M.D, 
Dr.KannanM.S.,M.Ch, Dr.T.G.BalachandarM.S.,M.Ch, for their unstinted 
encouragement,  guidance and valuable suggestions throughout the period of 
study. 
 
I am extremely thankful to Mr. Venkatesh statistician for analyzing the 
results. 
 
I take this opportunity to thank my parents, wife, and my children for their support.  
 
 
 
 
 
 
Predictors of Local Recurrence 
After 
Radiofrequency Ablation of Liver 
Tumors 
 
 
 CONTENTS 
 
 
 
Sl. No. Title Page No. 
1. Introduction 1 
2. Aim of the study 5 
3. Review of Literature 6 
4. Patients and Methods 36 
5. Results 43 
6. Discussion 48 
7. Conclusion 56 
8.      References 58 
9. Appendix 
Master Chart 
71 
 
 
 
 
 
 
Introduction  
          RADIOFREQUENCY (RF) energy has become a popular means of tumor ablation 
in recent years. Radiofrequency ablation (RFA) has been used to destroy malignant 
lesions of the lung, kidney, bone, adrenal glands, spleen, breast, lymph nodes, pelvis, 
prostate, neural tissue, and liver.1-8 The concept of tumor ablation has been used for 
more than 100 years. Many ablation modalities have been used, including 
cryoablation, alcohol ablation, laser, and microwave energy.9 Most recently, the use of 
RF energy for tumor ablation is becoming commonplace, most likely owing to its ease 
of use and availability, the multiple approaches of probe delivery, the wide range of 
applications, and the effectiveness of treatment.10  
 
              Hepatic resection offers the greatest potential for cure in patients with 
primary and metastatic liver tumors. Unfortunately, advanced stage, inadequate 
functional liver reserve, extrahepatic disease, or medical comorbidities render most 
patients with hepatic malignancy inoperable. Although complete surgical resection of 
HCC offers the best chance of long-term survival, cirrhosis may limit the amount of 
parenchymal resection that will be tolerated and increases the risk of postoperative 
liver failure and death.(11) 
 
            In most patients with cirrhosis and HCC confined to the liver, resection is not 
safe, and local tumor-ablation therapies are considered as alternative treatment 
options.Liver-directed therapies encompass a broad range of modalities from 
transarterial chemotherapy to intratumoral chemical injection and thermal 
destruction.  
 
 
 At present, the most popular and widely practiced local treatment modality is 
radiofrequency thermal ablation. RFA is a relatively new and minimally invasive 
therapy for primary and metastatic liver tumors. Early studies have suggested that 
this is an effective and safe technique for treating liver tumors (12–17). As a result, 
RFA is gaining popularity as the preferred modality of local ablation for unresectable 
liver tumors in many centers. (18-20) with its technical simplicity and safety, RFA has 
even been proposed as an alternative to hepatic resection for small liver tumors (15, 
17). 
 
             Radiofrequency ablation (RFA) is a thermal treatment technique designed to 
produce localized tumor destruction by heating tumor tissue to temperatures that 
exceed 50°C. When tumor cells are heated to temperatures above 45° to 50°C for more 
than 3 minutes, intracellular protein denaturation and melting of lipid bilayers results 
in direct tumor cell death. (21-24) RFA uses alternating current passed across needle 
electrode arrays placed directly into the tumor. Ionic stimulation induced by the 
alternating current in tissue surrounding the electrode array produces gradual 
frictional heating, and the tissue temperature rise to 80° to 110°C, which results in 
coagulative necrosis of the of the tumor tissue in proximity to the electrode.  
 
           The great majority of patients with colorectal liver metastases present with 
unresectable disease, The primary obstacles to complete resection in the majority of 
patients that present with colorectal liver metastases are the need to treat bilobar or 
bulky disease and the need to leave sufficient residual functional hepatic parenchyma 
after resection to support posthepatectomy hepatic function. Neoadjuvant 
chemotherapy, preoperative portal vein embolization, and 2-stage resection 
approaches contribute to an increase in the number of patients who can undergo 
potentially curative treatment (25-29). 
        
 Despite these innovative strategies, the great majority of patients with liver-only 
metastases from colorectal carcinoma are not candidates for complete surgical 
resection. To compliment resectional strategies when complete resection of all 
metastases is not possible, a number of tumor ablative techniques have been explored. 
Currently, the most widely used tumor ablative technique for treatment of colorectal 
liver metastasis is radiofrequency ablation (RFA), RFA combined with resection has 
recently been proposed as an option for unresectable patients. Thus, RFA has been 
reserved as an adjunctive tool to resection, when complete resection is not possible, 
either alone or in combination with resection (30). 
 
          Adequate ablation of hepatic tumors is feasible using RF energy. Percutaneous, 
laparoscopic, and open surgical approaches can be used to deliver RF probes to 
hepatic tumors. Multiple factors will affect patient survival, such as histological 
findings of the tumor, the use of adjuvant chemotherapy, and proper tumor staging. 
High-resolution CT and magnetic resonance imaging have clearly improved, increasing 
the sensitivity of these examinations 
           
 Local recurrence rate after radiofrequency coagulation (RFC) of liver tumors 
varies widely between 2% and 68%. While nearly all authors agree that tumor size is 
an important risk factor for local recurrence, little is known about the impact of other 
factors, such as tumor pathology, tumor location, or approach (31).  
 
      A meta-analysis of the published reports demonstrates that the size of the 
tumor to be treated is the most important factor in determining whether complete local 
ablation can be achieved. This largely stems from our current limitations of the extent 
of achievable coagulation from a given RF application, coupled with the need for 
treating a 0.5- to 1.0-cm surgical margin surrounding the target lesion. For lesions 
measuring 3.5 to 5.0 cm, 50% to 70% have been completely treated.33.Location also 
influences the possibility of achieving complete ablation of a tumor. If a tumor is near 
large vessels (ie, 5-10 mm, or those visible by means of CT), all of the malignant cells 
adjacent to the vessel are unlikely to be completely eradicated because of the 
previously described perfusion-mediated tissue cooling.36, 37  
 
         Other factors include the type of tumor, with greater clinical success reported in 
treating HCC33, 34, and breastmetastases38 compared with colorectal metastases. 
The tumor subtype can be equally important in determining outcome. The underlying 
parenchyma is also important, as previously described, with cirrhotic tissue serving to 
insulate the hepatomas, thereby promoting better thermal coagulation.33 Initial 
reported success with RFA in liver tumors is coupled with its low morbidity rate of 
7.1% for significant omplications.32, 34,35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Aim of the Study 
 
 
          The aim of this study was to identify and analyze the factors that may influence 
local recurrence to determine treatment efficacy, safety, local tumor control, and 
patterns of failure, treatment-related complications and outcome and overall survival 
in patients treated with Radiofrequency ablation for primary and metastatic liver 
tumors. 
Review Of Literature 
 
 
      Hepatic resection offers the greatest potential for cure in patients with primary 
and metastatic liver tumors. Unfortunately, advanced tage, inadequate functional liver 
reserve, extrahepatic disease, or medical comorbidities render most patients with 
hepatic malignancy inoperable. Clearly, other treatment strategies are necessary for 
those patients with 
unresectable tumors.Liver-directed therapies encompass a broad range of modalities 
from transarterial chemotherapy to intratumoral chemical injection and thermal 
destruction.  
 
 At present, the most popular and widely practiced local treatment modality is 
radiofrequency thermal ablation. Radiofrequency ablation (RFA) involves the insertion 
of a needle-type electrode into tumor tissue. An alternating current is then generated 
between the implanted electrode and a dispersive skin electrode, resulting in ionic 
agitation, frictional heating, and ultimately coagulation necrosis of the tumor tissue 
[1]. 
 
       With increasing use of RFA, a large body of data has accumulated on the safety 
and efficacy of this modality. However, most of the available studies consist of small 
nonrandomized trials or patient series (level 2 evidence). Few randomized, well-
controlled studies (level 1 evidence) have been published. Thus, it is difficult to 
compare RFA with other ablative modalities or the gold standard of surgery. The 
purpose of this review is summarize the available literature on RFA for hepatic 
malignancy.  
 
 
  
Radiofrequency Ablation 
 
Studies evaluating RFA in hepatocellular carcinoma 
 
       For patients with advanced cirrhosis who may not be able to tolerate resection, 
hepatic transplantation has emerged as the preferred treatment option. However, 
transplantation is largely reserved for hepatocellular carcinoma (HCC) and has several 
limitations, including strict selection criteria, limited availability of donor organs, and 
the need for lifelong immunosuppression. Thus, the majority of patients with 
unresectable hepatic tumors receive nonsurgical liver-directed therapies. A plethora of 
studies exist on the use of RFA in HCC.  
 
Studies of RFA alone: 
 
      Early RFA studies focused on its use as a stand-alone therapy for patients with 
unresectable HCC. While these trials contained valuable information regarding 
treatment safety and response, they lacked sufficient follow- up to define important 
long-term outcomes such as  
survival. Only recently have survival data become available on RFA-treated HCC 
patients. Large clinical series from Europe, the United States, and Asia have 
demonstrated 5-year post-RFA survival rates between 33% and 55%, comparable to 
those seen in series of hepatic resection [2–5].Several studies have evaluated long-term 
outcome and prognostic factors for patients with unresectable HCC treated by 
conventional RFA.  
 
       In Italy, Lencioni et al performed a prospective, intention-to-treat analysis on 206 
patients with unresectable HCC. These patients had Childs-Pugh A or B cirrhosis of 
predominantly hepatitis C origin; 187 patients were considered for RFA and 19 
patients were excluded from RFA  

treatment on the basis of unfavorable tumor location. The authors observed favorable 
overall 5-year survival rates in both the intention-to-treat (41%) and actual treatment 
group (48%). Through multivariate analysis,they identified Childs-Pugh class and 
tumor multiplicity as the significant predictive variables for survival [3].  
 
 Similarly, Guglielmi et al found Childs-Pugh class to be a significant predictor 
of survival in RFA-treated patients. These authors performed percutaneous RFA on 53 
patients with HCC from primarily hepatitis C virus (HCV)-induced cirrhosis. While 
overall 3-year survival in all patients was 45%, the 3-year survival rate of Childs-Pugh 
A cirrhotics was significantly better than that of Childs-Pugh B cirrhotics (83% vs 
31%) [6].  
 
       In addition to conventional RFA, the Italian literature has also addressed the role 
of novel radiofrequency technologies in the management of HCC. Two clinical series 
evaluated the use of expandable and internally cooled electrode designs in RFA of 
primary hepatic tumors. Buscarini et al compared conventional RFA electrodes with 
expandable electrodes for the ablation of unresectable HCC.  
 
 In this series, 88 patients were treated via percutaneous RFA, using either 
conventional or expandable electrodes. The majority of patients had Childs-Pugh A or 
B cirrhosis due to hepatitis C infection. Five-year overall and disease-free survival 
rates were 33% and 3%, respectively. While mean number of treatment sessions and 
local recurrence rates were lower in the expandable electrode group, no significant 
differences in overall or disease-free survival were appreciated between the 2 electrode 
designs [2]. 
        
 In another study, Giovannini et al evaluated the efficacy  of internally cooled 
electrodes in 56 patients with HCC. The majority of patients had Childs-Pugh A or B 
cirrhosis; alcohol was the most common etiology of cirrhosis, followed by HCV and 
hepatitis B virus (HBV) infection. Overall and disease-free 3-year survival rates of 
94.2% and 70.3%, respectively, were observed. Interestingly, patients with alcoholic 
cirrhosis fared better than those with a viral  etiology: 2-year survival rates were 
77.7% in the alcoholic cirrhosis group versus 57.7% in the viral-induced cirrhotic 
group [7]. While the aforementioned study shows that internally cooled electrodes 
prolong survival relative to historical untreated controls, more mature data are 
necessary to assess the efficacy of internally cooled electrodes versus other electrode 
designs. 
 
      In Japan, Shibata et al performed a randomized trial comparing internally cooled 
electrodes and expandable electrodes. A total of 74 patients with unresectable HCC 
underwent RFA: 38 with internally cooled electrodes and 36 with expandable 
electrodes. The authors found no difference between the 2 treatment groups in terms 
of overall and disease-free survival [8]. Thus, the aggregate data from Japan and Italy 
suggest that with respect to long-term and disease-free survival, all currently available 
electrode designs are equivalent.  
 
     In the United States, the role of open and laparoscopic RFA approaches as well as 
combination resection–RFA therapy has also been explored. Raut et al reported a large 
series of 194 HCC patients who were treated by percutaneous or open RFA at the M.D. 
Anderson Cancer Center in Texas. Patients included those with unresectable HCC 
(median tumor diameter 3.3 cm) and Childs-Pugh A, B, or C cirrhosis due primarily to 
HCV. Of the 194 HCC patients, 140 received percutaneous RFA, while 54 underwent 
anopen, intraoperative approach. Of the 54 patients treated with open RFA, 22 
underwent concurrent resection of additional hepatic lesions. Local recurrence 
developed in 53% of the 194 patients, the majority of which was intrahepatic. The 
overall complication rate was 12%, while overall 5-year survival was 55.4% [4]. 
Interestingly, a subset analysis of the percutaneous RFA, open RFA, and combined 
RFA and hepatic resection group showed no significant difference in 5-year survival 
among the groups. However, early survival in the combined RFA/surgery group was 
significantly lower, likely corresponding to the increased morbidity and mortality 
associated with resection in cirrhotic patients.  
 
     Unlike the experience with the open approach, laparoscopic RFA has produced less 
promising results. Berber et al observed an overall 3-year survival of only 38% in 
patients with unresectable HCC treated by laparoscopic RFA [9].In addition to the 
Western experience, a large volume of data has accumulated from East Asia on the 
use of RFA in HCC.  
 
     In Japan, Tateishi et al published an extensive series on RFA for HCC; 664 HCC 
patients from all Childs-Pugh classes were treated by RFA. The primary cause of 
cirrhosis in most patients was HCV infection. Patients with tumors larger than 2 cm 
underwent pretherapy transarterial embolization.Of note, the study divided the 
patients into two groups, based on previous therapy. Those patients who received no 
prior treatments for their tumor were deemed naive (319 patients), while those who 
underwent previous interventions were classified as non-naive (345 patients). Five-
year overall survival rates in the naive and non-naive groups were 54.3% and 38.2%, 
respectively [5]. Importantly, the study observed a higher incidence of needle track 
tumor seeding, likely reflective of the failure to perform tract cauterization. 
 
    Another study in Hong Kong evaluated the use of RFA in patients with subcapsular, 
surface tumors. Poon et al conducted a prospective, nonrandomized trial of 80 
patients with unresectable HCC. The majority of patients had Childs-Pugh A or B 
cirrhosis from HBV infection. In that series, 48 patients had subcapsular tumors, and 
32 had nonsubcapsular lesions. While patients with subcapsular tumors tended to 
have larger tumors, higher alpha-fetoprotein (AFP) levels, and lower platelet counts, 
they still had equivalent outcomes after RFA. One-year overall survival rates of 88.3% 
and 79.4% were observed in the nonsubcapsular and subcapsular patient groups, 
respectively. Equivalent morbidity, mortality, and recurrence rates were also noted.  
 
 Unlike other series, this study reported no incidences of needle track seeding or 
intraperitoneal metastasis associated with RFA of subcapsular tumors; the authors 
attributed their favorable results to their technique. Specifically, rather than puncture 
the tumor perpendicularly, the authors inserted the radiofrequency needle obliquely 
through a layer of nontumorous hepatic tissue; they also meticulously 
thermocoagulated the needle tract. Thus, procedural differences appeared to account 
for the lower recurrence rate observed in this study [10] (Table 1). 
 
Studies comparing RFA with other ablative modalities: 
 
Several comparative trials also have been conducted evaluating RFA against other 
conventional ablative modalities. The majority of these studies originated in East Asia 
and compare RFA to the standard chemical ablation techniques— ethanol and acetic 
acid injection. 
 
  In Taiwan, Lin et al performed a randomized controlled trial comparing RFA 
with percutaneous ethanol injection (PEI) and percutaneous acetic acid injection (PAI). 
A total of 187 patients with HCC less than 3 cm in size were randomized to receive 
RFA (62 patients), PEI (62 patients), or PAI (63 patients). Patients had primarily HBV 
induced Childs-Pugh A or B cirrhosis. End points of the study included tumor 
response, recurrence, survival, and complication rate. RFA-treated  

patients demonstrated significantly better recurrence and survival rates than their 
chemically ablated counterparts.  
 
 Further, the number of treatment sessions required to induce complete 
response was significantly less in the RFA treatment group. While RFA was superior to 
chemical ablation in terms of inducing responses, limiting recurrence, and prolonging 
survival, it was associated with a higher complication rate. In this series, 3 major 
complications, including 2 hemothoraces requiring thoracostomy drainage and 1 
gastric bleed/perforation, were observed in the RFA treatment group; in contrast, no 
complications were noted in the chemical ablation groups.Of note, the authors also 
conducted multivariate analysis to identify predictive variables for long-term outcome. 
Tumor size (>2 cm), Edmondson grade (I and II), and treatment method all correlated 
significantly with longterm survival and local recurrence [11].  
 
       In another large randomized trial, Lin et al compared RFA with both conventional 
and high-dose PEI regimens.Single-session PEI has been advocated as a viable 
therapeutic option for large HCCs not amenable to small-volume conventional ethanol 
treatment. In this study, the authors randomized 157 patients with HCC less than 4 
cm in diameter into 3 treatment groups: conventional PEI (52 patients), high-dose PEI 
(53 patients), and RFA (52 patients). All patients had Childs-Pugh A or B cirrhosis 
predominantly from HBV infection. As with their other study, the authors 
demonstrated significantly better long-term outcomes in the RFA-treated group. 
Compared to conventional and high-dose PEI, RFA required fewer treatment sessions 
to ablate tumors completely. It also was associated with lower local tumor progression 
rates and higher long-term survival rates [12]. 
 
      The superiority of RFA over chemical ablation was confirmed in a Japanese 
study by Shiina et al. In this series, 232 patients with HCC (_3 cm in diameter and 
fewer than 3 in number) were randomized to receive either RFA (118 patients) or 
ethanol injection (114 patients). Of note, the patient population of this study differed 
in that the majority of patients had cirrhosis secondary to HCV rather than HBV. No 
significant difference in complication rates was reported between the RFA and PEI 
groups. 
 
 However, as with the Taiwanese studies, the authors did observe decreased 
number of treatment sessions and increased long-term survival in the RFA cohort [13]. 
In another Japanese study, Omata et al retrospectively analyzed 1,238 patients 
treated with percutaneous ablation via ethanol injection, microwave coagulation 
therapy (MCT), or RFA. They noted superior 5-year survival rates in treatment-naive 
patients who underwent RFA as opposed to other percutaneous ablative therapies 
[14].  
 
          To assess the efficacy of combined ablative modalities in the management of 
HCC, a Chinese study compared the use of RFA and PEI versus RFA alone. A total of 
86 patients with single HCC less than 5.0 cm in diameter were randomized to receive 
either combination RFA-PEI (45 patients) or RFA alone (41 patients). No significant 
difference in survival was noted between the 2 treatment groups. Interestingly, a 
subset analysis of tumors greater than 3 cm in diameter revealed that the combination 
therapy group had higher local recurrence-free survival when compared to RFA-only 
treated patients [15]. 
    
        While the majority of comparative trials have analyzed RFA against chemical 
ablation, one study by Lu et al compared percutaneous RFA with microwave 
coagulation therapy (MCT). In this series, 102 patients with HCC and Childs-Pugh A 
or B cirrhosis of predominantly HBV origin underwent either RFA (n _ 53) or MCT (n _ 
49) [16]. Analysis of outcomes in the 2 groups revealed equivalent complete ablation 
rates, local recurrence rates, major complication rates, and long-term survival rates. 
However, this study was limited by several methodological flaws, including 
inhomogenous patient distribution and selection bias. Further study is needed to 
assess the relative efficacy of RFA and MCT to establish the role of each of these 
modalities in the algorithm of hepatic tumor management (Table 2). 
 
Studies comparing RFA with surgical resection: 
 
        Most studies evaluating RFA versus surgical resection show equivalent long-term 
outcomes with either treatment. Chen et al published a randomized controlled trial in 
which 112 patients with single HCC less than 5 cm in diameter received either 
resection (65 patients) or percutaneous RFA (47 patients). No significant differences in 
local recurrence, overall survival, or disease-free survival were detected between the 2 
treatment groups [17].Several nonrandomized studies also demonstrated equivalent 
outcome with RFA and surgery [18,19].  
 
     In Italy, Montorsi et al conducted a prospective, nonrandomized trial comparing 
laparoscopic RFA with surgery. The study population consisted of 98 patients with 
single HCC less than 5 cm in diameter and Childs-Pugh A or B cirrhosis of 
predominantly HCV etiology. Fifty-eight patients received RFA; 40 underwent 
resection. While long-term (4-year) survival was equivalent in both treatment groups, 
RFA resulted in significantly higher intrahepatic recurrence rates than resection. 
Multivariate analysis identified AFP level, treatment, and etiology of cirrhosis as 
independent risk factors for intrahepatic recurrence, whereas AFP level alone 
predicted survival.  
 
  
 Of note, local recurrence rates were significantly lower in RFA-treated patients 
in this study relative to others. The authors attributed this to improved heat efficiency 
from inflow occlusion performed during laparoscopy [20]. Another Italian study by 
Vivarelli et al compared surgical resection with percutaneous RFA. Unlike the majority 
of comparative trials, this study showed that long-term survival was higher in the 
surgical resection group, particularly in that subset of patients with tumors greater 
than 3.0 cm in diameter and early-stage cirrhosis [21]. However, these data are to be 
interpreted with caution as this study contained significant selection bias; most 
patients who underwent RFA had more advanced tumors and worse liver function 
than their resected counterparts (Table 3). 
 
Studies evaluating RFA for colorectal liver metastasis 
 
 RFA has been increasingly used for the treatment of colorectal liver metastases 
(CRLM). Herein, we present the available data on RFA for CRLM. As in our analysis of 
RFA for HCC, the relevant literature is grouped into 3 categories: (1) studies evaluating 
RFA alone, (2) studies 
evaluating RFA plus surgical resection, and (3) studies evaluating RFA with other 
modalities. 
 
Studies evaluating RFA alone: 
            One of the earliest studies on RFA for CRLM was a clinical series published by 
Curley et al at M.D. Anderson Cancer Center. The authors reported 123 patients with 
unresectable primary and metastatic hepatic tumors who underwent RFA by either a 
percutaneous or open surgical approach. Sixty-one of the 123 patients had 
unresectable CRLM. In these patients, local recurrence rate was 1.8%, while new 
metastatic disease developed in 27.6% of patients. No deaths were reported, and the 
complication rate was 2.4%. The lack of long-term survival rates is a  

 significant drawback to this study; nonetheless, the series does demonstrate a 
favorable safety profile for RFA in unresectable hepatic metastases. Furthermore, the 
study also shows an impressively low local recurrence rate when compared to similar 
studies published by other authors. This is likely a factor of patient/tumor selection; 
the median diameter of treated lesions was only 3.4 cm. Similarly, the rate of new 
metastatic disease is one of the lowest reported; rates typically range between 40% 
and 80% [22]. 
 
        In 2000, De Baere et al presented data on 68 patients treated with RFA, 58 of 
whom had unresectable CRLM. Rates of local tumor progression and major 
complication were 16% and 4.4%, respectively. Although both percutaneous and open 
approaches were used, comparisons could not be made between the 2 approaches due 
to significant differences in lesion diameter between the 2 groups. Nevertheless, this 
study provides valuable information regarding the potential etiology of local 
recurrences after RFA treatment. According to the authors, the use of a single needle 
instead of a cluster needle for RFA of lesions greater than 2.5 cm could have been 
related to the number of local recurrences. However, there is no evidence from other 
clinical series demonstrating that cluster needles produce a more efficient or more 
complete ablation of lesions greater than 2.5 cm, as compared to conventional single-
needle designs [23]. 
 
        In 2001, Guilliams et al from the United Kingdom analyzed 69 patients with 
unresectable CRLM treated by percutaneous  RFA. Eighteen of the 69 patients (26%) 
had undergone previous hepatic resection, and 20 (29%) had extrahepatic disease at 
the time of treatment. Of note, this is one of the first studies to present long-term 
survival data following RFA; median survival was 27 months, with a 4-year overall 
survival rate of 22%. The authors reported significantly better median survival in 
patients with  
fewer than 4 lesions, each smaller than 5 cm in diameter, compared to those patients 
with multiple, larger tumors (33 months vs 15 months) [24].  
 
 A second series by Guilliams et al showed similar long-term survival data. In 
this study, the authors used percutaneous RFA to treat 73 patients with unresectable 
CRLM. Median survival after RFA was 31 months, and 5-year survival rate, 25% 
[24,25]. Of note, some patients received other therapies prior to RFA, including 
systemic chemotherapy (80%), liver resection (19%), and laser interstitial therapy 
(13%). While it is difficult to assess the effect of RFA alone on survival, this is one of 
the few studies with RFA that contains any long-term survival data. 
 
  Adding to the European experience, an Italian group published a study 
documenting long-term outcomes after RFA for CRLM. In 2001, Solbiati et al 
presented data on 117 patients with colorectal hepatic metastases, all treated by RFA 
through a percutaneous approach. Median survival was 36 months and 3-year 
survival rate, 46%. No significant correlation was found between the number or size of 
the lesion and the time until death. Local recurrence rate was 39.1%; new hepatic 
metastases appeared in 57% of patients.Despite finding a significant association 
between lesion size and timing and frequency of tumor local recurrence, survival rates 
remained unaffected by lesion size [26].  
 
An interesting finding mentioned by this study is the effect of repeat treatment 
on patient survival. In this series no significant relationship was found between 
survival rates and repeated treatment of lesions; however, a non-significant trend 
toward longer survival was observed. This raises some interesting questions: Would 
using a larger sample size enable the detection of a significant survival advantage from 
re-treatment? If so, should re-treatment of locally recurrent tumors become the new 
paradigm? Should new hepatic lesions in previously treated patients also  
be ablated? Larger, more rigorous clinical trials are needed to answer these 
questions (Table 4). 
 
Studies evaluating RFA plus resection: 
 
       The role of RFA combined with surgical resection has also recently been 
explored. In 2003, Pawlik et al published a prospective analysis of 124 patients with 
multifocal CRLM who underwent combination RFA and resection. RFA and resection 
were performed during a single operation; median number of tumors excised was 2, 
and median number of tumors 
ablated was 1. Patients underwent a wide range of resections depending on location of 
the lesion. RFA was performed for unresectable lesions. The overall complication rate 
from RFA plus resection was 19.8%, while overall mortality was 2.3%, falling within 
the range of mortality (0–3%) reported for hepatic resection alone; 2 of the 4 deaths 
were related to liver failure [1,27]. The local recurrence rate (8.2%) was comparable to 
other studies. Multivariate analysis determined that only the number of tumors (_10) 
was significantly associated with a short time to recurrence; factors such as age, 
position of metastasis, and size of metastasis were not significant. Median survival 
was 45.5 months, with lesions greater than 3 cm associated with significantly higher 
mortality than smaller ones.  
 
      In 2004, a second study from M.D. Anderson was published, evaluating the use 
of RFA plus resection in the treatment of CRLM. Abdalla et al presented 428 patients 
who underwent treatment for colorectal liver metastases: 348 patients received 
resection (55%), resection plus RFA (29%), or RFA (16%) alone, whereas 70 patients 
were 
treated with chemotherapy alone. Of note, this study is the first and only published 
trial comparing resection, RFA, and RFA plus resection with chemotherapy in 
unresectable CRLM patients.  
  The overall recurrence rate varied significantly between treatment arms, with 
the highest rate of recurrence of any kind occurring in the RFA only group (84%), 
followed by RFA plus resection (63%) and resection only (52%). Similarly, local 
recurrence was more common after RFA only (9%), compared with RFA plus resection 
(5%) and resection only (2%). Long-term survival was higher in the resection-only 
group; however, no significant difference was detected between the RFA plus resection 
and RFA-only groups [28].Of note, multivariate analysis revealed tumor number to be 
significantly predictive of survival. Overall survival was best for patients with solitary 
tumors, intermediate for patients with 2 or 3 tumors, and worst for patients with more 
than 3 tumors.  
 
 In this study, when the survival rate of all patients that had RFA as a 
component of their therapy was compared to the survival rate of the chemotherapy 
control group, a significant difference was detected in favor of RFA treatment. To be 
fair, any conclusions drawn from this study must take into account the significant 
differences in patient characteristics among the treatment groups. A future 
randomized study would be helpful to control for differences in patient characteristics.   
 
 In addition to the US studies, a French group headed by Elias et al reported 
their experience with 63 patients with CRLM receiving combination surgical and RFA 
therapy. Anatomic hepatic resection was used for large or multiple tumor clusters; 
wedge resection for superficial, small or scattered metastases, and RFA for small, 
central metastases. The authors observed a median overall survival of 36 months, with 
a 3-year survival rate of 47%. The local recurrence rate after RFA was 7.1%, similar to 
the local recurrence rate observed after wedge resection (7.2%) and formal 
hepatectomy (9%). Poor clearance margins likely contributed to the higher local 
recurrence rate observed with RFA in this study compared to  
others [29]. As expected, the local recurrence after RFA was significantly higher for 
lesions close to vascular structures and those with diameter greater than 3 cm [30] 
(Table 5). 
 
Studies evaluating RFA plus other therapies: 
 
  The role of RFA with hepatic arterial chemotherapy and systemic chemotherapy 
also has been the subject of recent investigation. Cheng et al compared patients 
receiving laparoscopic RFA (LRFA) alone, laparoscopic hepatic arterial infusion pump 
therapy (LHAIP) alone, and a combination of the 2 therapies. A total of 45 patients 
were included in the analysis: 20 in LRFA-alone group, 10 in the LHAIP plus LRFA 
group, 
and 15 in the LHAIP group. All patients had unresectable CRLM and no evidence of 
extrahepatic disease. Of note, patients receiving LHAIP did have more diffuse tumor, 
increased evidence of vascular invasion, and a higher frequency of multiple segments 
involved. Otherwise, the treatment 
groups did not vary significantly in terms of patient or laboratory characteristics. A 
Kaplan-Meier estimate of survival for the 3 treatment groups revealed the following: 
the actuarial survival rates were 70%, 67%, and 50% for the LRFA-alone, LRFA plus 
LHAIP, and LHAIP-alone groups, respectively. Mean follow-up was 11.5 months only. 
Estimated mean survival time in the LRFA group was 25.8 months, in the combined 
group, 15.2 months, and in the LHAIP alone group, 12.6 months [31]. 
 
       In 2002, Scaife et al at M.D. Anderson, in collaboration with Pascale National 
Tumor Institute in Italy, conducted a prospective study examining the feasibility of 
adjuvant HAI after RFA alone or RFA plus resection for CRLM. Included in the analysis 
were patients with 7 or fewer metastatic lesions not amenable to resection but 
amenable to RFA or those with smaller tumors amenable to RFA and larger tumors 
amenable to resection. A total of 51 patients underwent RFA with 31 of those receiving 
hepatic resection. Median follow-up was 20 months and only 62% of the patients 
completed the course of chemotherapy [32]. The authors concluded that RFA with HAI 
is feasible. The study did not comment on differences in long-term survival between 
the resection and non-resection group.  
 
      In 2006, Machi et al reported their results with combination RFA and systemic 
chemotherapy. In their study, 100 patients with CRLM were treated by RFA; 55 
underwent RFA followed by systemic chemotherapy, while the remainder received 
systemic chemotherapy first, then RFA. The initial chemotherapeutic regimen 
consisted of fluorouracil and leucovorin; this was later supplanted by the newer agents 
oxaliplatin and irinotecan. While local recurrence rate was 6.7%, new intrahepatic and 
extrahepatic metastasis occurred in 87% of patients.  
 
 Univariate and multivariate analysis showed that the following factors 
correlated significantly with overall survival: age, total tumor size, extrahepatic 
disease, RFA approach, previous therapeutic chemotherapy, and carcinoembryonic 
antigen (CEA). Patients treated by RFA via a laparoscopic approach had the longest 
survival, although significant differences existed in patient and tumor characteristics 
among the various procedural approach groups. Overall 5-year survival rate for all 
patients was 30.5%. Of note, a significant difference was observed in the median 
survival time between the group that received chemotherapy after RFA and the group 
that received chemotherapy before RFA (48 months vs 22 months, respectively) [33] 
(Table 6). 
 
 
 
 
 
The role of RFA in treatment of hepatic malignancy 
 
Radiofrequency ablation and hepatocellular carcinoma 
 
      In the management of HCC, RFA is typically used as a stand-alone alternative to 
resection in unresectable patients or as an adjunct to surgery and/or other ablative 
modalities in total cancer therapy. 
 
RFA as an alternative to other ablative modalities 
 in unresectable HCC: 
           
  Chemical ablation by ethanol injection was once touted as the treatment of 
choice for patients with unresectable HCC. However, with improvements in 
technology, RFA has now become the preferred ablative modality for unresectable 
hepatocellular cancer. Long-term survival and recurrence rates are superior with 
percutaneous RFA compared to conventional chemical ablation (ethanol or acetic acid 
injection) [5,8,13]. While some studies show a higher complication rate with RFA, this 
does not translate to an increase in mortality [11,12]. 
 
RFA as an alternative to surgical resection: 
 
          Both level and 2 evidence show that survival rates after RFA are comparable to 
those of surgical resection [17–20]. However, the local recurrence rates after RFA 
treatment appear uniformly higher than that of surgery alone [9,17,18,20]. The 
significance of these results remains to be determined. First, local recurrence rates 
after RFA vary significantly 
among studies, particularly those of different geographic regions. This is likely 
reflective of multiple factors including extent and etiology of cirrhosis, which 
themselves correlate with geographical location. In the West and Japan, HCV is more 
prevalent, whereas in China HBV is the predominant etiologic agent of cirrhosis. The 2 
viral types produce significantly different patterns of local recurrence and disease 
progression, with HCV tending to produce multifocal cirrhotic nodules. Even more 
important, the higher local recurrence rate observed with RFA does not negatively 
impact long-term survival. Thus, the bulk of the literature on RFA and resection show 
the 2 treatments to be equivalent in terms of meaningful outcomes such as survival. 
 
RFA as an adjunct to surgery or other ablative modalities: 
 
         Limited data exist on the use of RFA in conjunction with surgery or other 
ablative modalities. The only study that compared percutaneous RFA, open RFA, and 
combination RFA–surgical resection found no difference in long-term survival or local 
recurrence rate among the treatment groups. Interestingly, this study showed an 
increase in early mortality in the combination surgery–RFA group, likely reflective of 
the morbidity and mortality associated with major hepatic resection [4]. Given that the 
combination of RFA and surgery is usually reserved for select patients with multifocal 
lesions, it is difficult to compare this use of RFA with other indications, as inherent 
selection bias already exists. Nevertheless, RFA appears to be a promising adjunct to 
resection in patients with multifocal lesions who would otherwise not be able to 
tolerate resection alone.The use of RFA plus other ablative therapies like PEI also has 
been studied. The combination of RFA with PEI appears to offer no significant survival 
advantage over RFA alone. However, for larger lesions between 3.1 and 5.0 cm, 
combination therapy produces better local recurrence-free survival [15]. Thus, while 
the combination of thermal andchemical ablation does not affect long-term overall 
survival in HCC patients, it may reduce local recurrence. Further study is needed to 
confirm this. 
       
 The use of RFA as a bridge to transplantation also has been explored in HCC 
patients. Liver transplantation offers significant advantages over resection and 
ablation in that it ensures complete removal of all hepatic foci tumor and cures the 
underlying disease process (cirrhosis). RFA has 
been shown to be a safe and effective bridge to hepatic transplantation, inducing 
responses in the majority of lesions. However, no comparison of transplantation rates 
and post-transplantation survival rates have been performed between RFA-treated and 
non–RFA-treated patients; further study is needed.  
 
Summary of evidence-based recommendations for RFA in HCC 
 
The following are acceptable uses for RFA: 
 
1. Primary therapy for unresectable HCC less than 3.0 cm in size: 
   level 1 and 2 evidence. 
2. A potential alternative to surgery for resectable HCC: 
   level 1 and 2 evidence. 
3. Combination treatment with surgery for multifocal HCC:  
   level 2 evidence. 
4. Combination treatment with chemical ablation for large HCC (_3 cm): 
    level 2 evidence. 
 
 
 
 Review of the literature supports the following conclusions: 
 
1. No available electrode design offers significant advantages over another   in terms of 
long-term and disease-free survival. Level 2 evidence. 
 
2. Procedural approach to RFA (percutaneous versus open) does not significantly 
impact long-term outcome in HCC therapy. Level 2 evidence.  
 
3. For surface lesions, the RF needle should be inserted obliquely through a layer of 
nontumorous hepatic tissue, and the needle tract should be thermocoagulated to 
minimize the risk of hemorrhage and needle tract seeding. Level 2 evidence.  
 
4. Childs-Pugh score is the most commonly identified determinant of survival after 
RFA for HCC. Level 1and 2 evidence. 
 
5. RFA is a safe and promising bridge to transplantation; however, insufficient 
evidence exists to determine if RFA improves transplantation rates and post-
transplantation 
 
RFA and colorectal liver metastases 
  
 RFA has emerged as the most widely accepted ablative modality for the 
treatment of CRLM. However, to date, all of the data on RFA for CRLM consists of level 
2 studies. There is currently no level 1 evidence (randomized controlled trials) 
comparing RFA with surgical resection or 
other ablative therapies. In the following discussion, the previously presented data on 
RFA in CRLM is analyzed for patterns in local recurrence, survival, and complications. 
Specific recommendations are then provided, based on this analysis. 
 
 
 
 
Local recurrence: 
         
  Unlike in HCC, local recurrence and intrahepatic progression are related to 
survival in patients with unresectable CRLM. Several factors have been identified as 
determinants of local recurrence and hepatic progression, including tumor size, 
proximity to large vessels, and radiofrequency probe design. Tumor size is the most 
commonly reported variable affecting local recurrence [26,34 –36]. The critical cutoff at 
which recurrence rates appear to dramatically increase is between 2.5 and 3.0 cm; 
this is likely reflective of the maximum diameter of ablation achievable with current 
RFA technology.  
        
 New probe designs have been developed in an attempt to overcome limitations 
in ablation size. Ahmad et al compared the local recurrence and survival rates in 
CRLM patients ablated with a newer probe design versus conventional designs; they 
observed an improvement in median disease-free survival and margin recurrence rate 
with the newer probe design [37]. However, significant bias exists in this study as 
those patients treated by the new RFA probe design also received newer and 
presumably more effective systemic chemotherapeutic regimens. Thus, lesions larger 
than 3 cm, particularly those between 5 and 7 cm, are most susceptible to local 
recurrence due to limitations in current RFA technology. 
       
 Another factor often cited as a crucial determinant of local recurrence after RFA 
is the proximity of tumor to large blood vessels. The “heat sink” effect of blood flow 
reduces temperature and prevents complete ablation by RFA. The end result is local 
recurrence at the margin between tumor and blood vessel. As mentioned previously, 
local recurrence rates vary markedly between studies. Several reasons account for this 
including differences in data collection, patient characteristics, and tumor biology. 
Rates of local recurrence range from 1.8% in 1 study to as high as 44% due to marked 
differences in data collection time.  
           
 Other authors report local recurrence rates between 9 and 21% [23,24]. Though 
it is difficult to determine, it appears that the use of RFA as part of multimodal cancer 
therapy (ie, RFA _ HAIP or RFA _ systemic chemotherapy) reduces local recurrence 
more than RFA alone. Recurrence rates after RFA combined with systemic or hepatic 
chemotherapy range from 4% to 7.1% [28,33,36] in general, lower than those observed 
with RFA alone. 
 
Overall survival: 
      
   Lack of long-term survival data, coupled with differences in treatment 
regimens (ie, RFA alone vs RFA plus other therapies), makes overall survival difficult 
to analyze in patients with unresectable CRLM treated by RFA.The first study 
containing long-term outcomes data for RFA in CRLM showed 2-, 3-, and 5-year 
survival rates of 60%, 34%, and 22%, respectively. While lower than the 58% 5-year 
survival rate reported by Abdalla et al for resection, these rates were clearly higher 
than systemic chemotherapy alone (22% to 27% at 2 years with traditional 5-
fluorouracil– based regimens) [24,28,30,38,39].  
      
 Improvements in RFA technology and application as well as patient selection 
have led to some improvement in survival rates after RFA, with 5-year survival rates in 
more recent studies ranging from 25% to 30.5% [28,33]. Still, these rates remain lower 
than those observed with resection alone; thus, the level 2 evidence  supports the use 
of RFA for unresectable liver metastasis, but not as an alternative to resection in 
appropriate surgical candidates with resectable disease. 
 
Complications: 
 
       Overall, RFA is a safe modality for the ablation of unresectable CRLM. Minor and 
major complication rates from RFA alone range between 2.4%–12% and 0–5.8%, 
respectively, with only 1 death reported. When RFA is combined with systemic 
chemotherapy, both minor and major complication rates (12.3% and 4.8%, 
respectively) do not appear to increase. Similarly, the use of RFA in conjunction with 
surgery does not appear to increase the rate of major complications (3.5%–4%), 
although minor complication rates (6%–16%) and risk of death (4 total deaths) may be 
higher [40]. Most deaths from combined RFA and resection are due to liver failure, 
indicating that functional hepatic reserve is an important consideration when selecting 
patients to undergo combined RFA and resection. 
        
 Another important consideration with respect to preventing or reducing 
complications from RFA is procedural approach. Current thought favors the open and 
laparoscopic approach for several reasons, including improved staging accuracy with 
intraoperative ultrasound, less risk of injury to adjacent organs, and less potential for 
fatal complications. However, the use of a percutaneous approach by experienced 
radiologists has shown minor and major complication rates (4% and 6%–12%, 
respectively) that are comparable to the complication rates of open approaches [41,42].  
       
  Thus, in experienced hands, percutaneous RFA is as safe as open or 
laparoscopic RFA, and in fact is ideal for select circumstances such as patients who 
are poor candidates for general anesthesia or tumors located in the periphery of the 
liver. Based on the aforementioned analysis of RFA in CRLM,the authors provide the 
following recommendations for the use of RFA in CRLM. 
 
Summary of evidence-based recommendations for RFA in CRLM 
 
The following are acceptable uses for RFA: 
 
1. Primary therapy for unresectable CRLM less than 3.0 cm in size: 
    level 2 evidence. 
2. Combination treatment with surgery for unresectable CRLM:  
    level 2 evidence. 
3. Combination treatment with HAIP for unresectable CRLM: 
    level 2 evidence. 
4. Combination treatment with systemic chemotherapy 
    for   unresectable CRLM: level 2 evidence. 
5. RFA may be feasible in the treatment of recurrent CRLM;  
    however   limited or no data is available to assess outcome benefits. 
 
 
 
. 
Patients And Methods 
        
 Between June 2005 and June 2007, 23 patients with 55 hepatic tumors 
underwent RFA at the  Department of Surgical gastroenterology,Govt Stanley medical 
college hospital ,Chennai. Among these, 18 were male and 5 were female. Mean age of 
patients was 67 years (range 36–82). All patients were diagnosed by biopsy at least on 
one lesion. Twelve were hepatic cellular carcinoma (HCC) patients (25 tumors), with 
mean diameter of 3.3 cm (range, 2-7 cm). Of these 12 HCC patients, 8 were cirrhotic. 
Eleven   patients (17 tumors) had metastatic liver carcinomas (MLCs) with mean 
diameter of 2.5 cm (range, 1.5- 4 cm). The primary tumors were from colorectal tract 
(n=6), neuroendocrine 
(n= 2),gastrointestinal stromal tumors(n = 3)respectively(Table1).  
  
Equipment 
         
 All RFA treatments were performed under a standard protocol .The RF system 
used in this study was a 460-kHz impedance-controlled radiofrequency generator 
Berthold (Tuttlingen,Germany) has a monopolar electrode that contains small holes for 
saline perfusion. Perfusion reduces tissue impedance and allows larger zone of 
ablation. That is capable of delivering a maximum power of 150 W through a 14-G 
electrode. The electrode contained prongs that could be deployed from the cannula, 
when the cannula was inserted into the surface of the tumor. The high-frequency 
electric current was passed through the deployed prongs to the tumor tissue, causing 
the vibration and friction of ions in the tissue, resulting in the temperatures of up to 
100, which produced a sphere like coagulation area of 2.0-3.0 cm in diameter. The 
time to produce a 5-cm ablation sphere was about 20 min. If multiple-overlapping 
ablations were required to ablate large tumors, much more time was needed.  
 
Team Approach 
        
 To concentrate and strengthen expertise of the treatment and to facilitate 
research on this new treatment modality, a team comprising hepatobiliary surgeons 
with substantial experience in the management of liver cancers and interventional 
radiologist with experience in interventional procedures in the liver was responsible for 
this treatment in our institution.  
 
Size 
  
 Patients with<3 tumors, each < 5 cm in diameter, were considered the favorable 
candidates for RFA. However, we also offered RFA to selected patients with more than 
3 tumor nodules or tumors larger than 5 cm (up to 7 cm) if no other effective 
treatment options were available and if the liver function was satisfactory. Ablation 
was performed with a curative intent, aiming to achieve a margin of 1 cm. The ablation 
area should cover the tumor and at least 0.5-1.0 cm of the surrounding tissue, and 
the margin should even be more than 1 cm when the tumor border was unclear. 
 
Technique  
  
 The treatment protocol was decided according to the ablation range. The 
hepatic tumor treated was identified by means of Ultrasound .The RF probe was then 
advanced to the desired margin of the tumor. Baseline tissue impedance was 
measured. In larger tumors, the RF electrode was then repositioned into a new site of 
the tumor under image guidance and with continuous temperature monitoring. When 
the temperature of the new position was near the cytotoxic threshold of 55°C, a second 
ablation was performed to create overlapping zones of thermocoagulation. The 
echogenic response during US guidance was also used as a rough approximation of 
the size of the ablation sphere when repositioning the electrode into a new region of 
the untreated tumor. During the ablation process, real-time ultrasound scan was 
performed to monitor the electrode placement and the ablation, and post-ablation 
ultrasound was performed to find the potential complications so that the 
corresponding measures could be carried out in time. 
 
 
Table 1. Characteristics of Patients who 
 underwent   Radiofrequency Ablation 
__________________________________________________________________ 
                                      Variable Number (n) Percentage (%) 
Gender 
          Male                              18                        78 
          Female                            5                        22 
Age (year) 
         <60                                   17                     74              
         >60                                    6                      26 
 Pathology 
           HCC                               12                      52 
           CRLM                              6                       26                   
           NELM                              2                        9 
           GIST                                3                      13 
Cirrhosis 
           Yes                                  8                       35            
           No                                  15                      65 
Hepatic resection 
           Yes                                   9                      39              
           No                                  14                      61             
PVL 
           Yes                                   6                      26              
           No                                  17                      64 
_____________________________________________________________             
Approach 
        
  The decision for the ablation approach used was made between the surgeon 
and interventionist and was based on the patient’s performance status and the size, 
location, numbers,and histological features of the tumor. Patients with small tumors 
located in a position amenable to percutaneous RFA were treated with this approach. 
Open approach was offered in the following situations: (1) large tumors that require 
multiple ablations even with the clustered probe; (2) tumors located near the dome of 
the liver, for which percutaneous ablation will cause pneumothorax or damage to the 
diaphragm; or (3) tumors located near the visceral organs such as the gallbladder, 
colon, or stomach.  
 
In selected patients without previous upper abdominal operation, laparoscopic 
approach was used instead of the open approach if the tumor position was favorable. 
All patients were reviewed by the team before the approach of RFA was decided. Tumor 
pathology was confirmed by percutaneous fine needle aspiration cytology for patients 
undergoing percutaneous RFA, and by core-needle biopsy for those undergoing 
laparoscopic or open RFA. A dose of intravenous antibiotics (Third generatin 
cephalosphorin) was given just before RFA. 
 
Anesthesia 
      
  All patients underwent RFA under general anesthesia or conscious sedation. 
Percutaneous ablation was performed with ultrasound guidance under local 
anesthesia. Intravenous sedation was routinely given before insertion of the needle 
probe in addition to local anesthesia. The abdomen and chest were prepared and 
draped under sterile conditions. Local anesthetic was injected at the skin puncture 
sites. The RF probes were passed percutaneously into the hepatic tumors with 
realtime image guidance. Full sedation was provided only after the ablation process 
had been started, which usually caused more pain than the needle puncturing itself.  
 
 
Table. 2. Tumor Characteristics and Approach of RFA 
________________________________________________________________ 
                                                       (n) (%) 
No. of tumors   
         Solitary     5 22 
         Multinodular 
             2-3                                     13 57                 
             >3                                        5 22  
Size of the  tumor  
             ≤3                                       17       74               
             >3                                  6        26       
Approach of ablation 
          Percutaneous                        11 48 
          Open                                     10 43 
          Laparoscopic                           2   9  
___________________________________________________________ 
 
Ablation  
       
 All open or laparoscopic ablations were performed by the surgeons under the 
guidance of intraoperative or laparoscopic ultrasound under general anesthesia. The 
ablation was performed using an automatic impedance control mode in which the 
current output was automatically adjusted according to the impedance at the needle 
tip. Temperature at the needle tip was also monitored. The needle tip was 
continuously perfused with cold saline via an internal channel inside the needle 
throughout the ablation to maintain the temperature below 20°C, thus preventing 
charring around the needle tip.The duration of each ablation cycle was set at 15 
minutes according to the recommendation of the manufacturer of the RFA system.  
 
Assessment of therapeutic efficacy 
   
 To evaluate the tumor response to RFA therapy, contrast enhanced CT was 
performed 1 month post-ablation and the complete ablation of the tumor was 
considered to be achieved if the scans revealed: (1) the ablation zone was beyond the 
tumor borders, (2) the margin of the ablation zone was clear and smooth, and (3) no 
contrast enhancement was detected within or around the tumor. Subsequently, the 
patients were monitored regularly for intrahepatic recurrence in the outpatient clinic 
by a follow-up protocol including serum α-fetoprotein (AFP) Carcino embryonic 
antigen(CEA), abdominal Ultrasound(US) and Contrast enhanced CT every 2-3 months 
for the first year, and then AFP,CEA every 2-3 mo, abdominal US and enhanced CT 
every 4-6 months after the first year.Postprocedural adjuvant systemic chemotherapy 
was offered to patients on the basis of their performance status and the histological 
features of their disease.  
  All patients were followed up to detect acute or chronic complications related to 
the RFA treatment. Suspected intrahepatic recurrence was confirmed by percutaneous 
fine needle biopsy. Local recurrence was defined as tumor recurrence within or at the 
periphery of the ablated lesion in the follow-up CT scan.Distant intrahepatic 
recurrence referred to a new tumor that appeared in the liver separated from the 
ablated area. Patients were followed-up for 6-34 months.  
 
Clinical data  
 To prospectively evaluate the results of the treatment, the clinical data of all 
patients were prospectively collected in a computerized database. The Institutional 
Review Board of our institution approved the treatment protocol and the collection of 
data. The initial 23 consecutive patients with liver tumors treated with RFA in our 
institution over a period of 24 months were the subjects of this study. 
 
Statistical Analysis 
 
 In univariate analysis, recurrence rates were compared between groups by a x2 
or Fisher exact test. Comparison between groups was performed using x2 test with 
Yates correction (or Fisher exact test where appropriate) for nominal variables. All 
statistical analyses were performed using the SPSS 10.0 for windows statistical 
package (SPSS Inc., Chicago, IL). A P value of < 0.05 was considered to be statistically 
significant. 
 
Results 
 
 
Patient Demographics 
  
 During the study period 23 patients underwent RFA procedures to ablate 12 
patients with hepatocellular carcinoma (52%) and 11 with metastatic (48%) hepatic 
tumors (Table 1) shows the clinical characteristics of the patients. The most common 
indication for RFA was HCC (52%). Colorectal metastasis was the most common type 
of liver secondaries treated (6 patients). Other types of liver secondaries included 
metastases from neuroendocrine tumor (2 patients), and gastrointestinal stromal 
tumor (3 patient). The majority of patients with HCC had underlying cirrhosis in 
association (8/12). These patients underwent 44 radiofrequency sessions, which were 
used to treat 53 tumors (25 -primary, 28-metastatic). The series included 18 men and 
5 women, mean age   67 years (range 36-82). Mean follow-up was 21.3 months (range 
1-34 months).  
 
Hepatic resection, and Portal vein Ligation 
  
 Out of 23 patients 9 had previous hepatic resection, and RFA was employed to 
treat intrahepatic tumor recurrences and tumors in remnant liver. Eight patients 
underwent hepatectomy, major hepatectomy for five (Right hepatectomy for  three left 
hepatectomy for two)and left lobectomy  and  non anatomical resections for three. 
Portal vein ligation was performed in 9 patients either open RFA or hepatic resection.  
 
 
 Tumor characteristics 
   
 For the 53 tumors treated in 23 patients 5patints (22%) had solitary 
tumors,multinodular in 18 patients(78%)[2-3(13),>3(5)].Size of the tumor <3cm in 17 
patients(74%)and >3 in 6 patients(26%). Mean tumor size was 23 mm (range 15-70 
mm) in HCC and 25mm(range 15-40 mm) in metastatic tumors. 
 
Radiofrequency procedure 
  
 For the 53 tumors treated in 23 patients, 11 were treated 
percutaneously(48%)and 12 via a surgical approach (52%) (Laparoscopic approach for 
two ). Ultrasound guidance was used for all sessions for a percutaneous 
procedure.Intraoperative Ultrasound used for open surgical approach.Mean duration 
of the radiofrequency sessions was 20.8+12.7 minutes (range 6-88 min). Median 
duration was 16.7 minutes. Overall, complete tumor ablation was observed in 18 of 
the 23 patients (78 %) who had the post ablation CT scan assessment. Five patients 
had incomplete ablation, 3 after percutaneous RFA and 2 after open RFA. Among 
these 5 patients, 3 had residual tumor at the deep margin. These patients were 
reablated after CT assessment. 
 
Hospital stay 
        
 Mean hospital stay was 7.3 +5.2 days (range 2-24 days).For the 11 
percutaneous procedures, mean hospital stay was 5 +3.8 days. For the 12 surgical 
procedures, mean hospital stay was 11.2 +5 days. 
 
 
Table. 3. Complications After Radiofrequency Ablation (5/23) 
________________________________________________ 
Complication                           Number (n)            Percentage (%) 
Liver dysfunction                        2                             9 
Intraperitoneal bleeding              1                             4 
Bilioma                                       1                             4 
Liver Abscess                              1                             4 
 
 
Morbidity and mortality 
       
  Five patients presented with complications during their hospital stay, giving a 
hospital morbidity of 22%. Post procedural liver dysfunction occurred in 2 patients 
(9%), Bleeding in 1 patient (4%)one patient developed liver abscess and bilioma in one 
patient (Table. 3). One patient (4.3%) died due to liver dysfunction giving a hospital 
mortality of 4%. This cirrhotic patient underwent hepatic resection for hepatocellular 
carcinoma and died 28th day after procedure from liver failure.  
 
 
Survival 
 
 Patients were divided into two groups for the survival analysis: hepatocellular 
carcinoma or metastasis from colorectal and other prrmaries. Overall survival rates for 
the hepatocellular carcinoma group  were 83%, 66%, 42%, at 6months,1, and 2 years 
respectively. For the metastasis group the overall survival rates were 91%, 90%, 64%, 
at 6months 1,  and 2 years respectively .Patients who had recurrence had a 
significantly lower survival rate (P = 0.04)  (TABLE 4)  
 
Recurrence 
    
 At 2 years 17 of the 53 tumors treated by radiofrequency ablation recurred in 
14 patients (26.4%). In the metastasis group (considering all types of primary tumors) 
7 of 28 tumors recurred (25%). In the hepatocellular carcinoma group, 7 of 25 tumors 
recurred (30%).(Table 5)Univariate analysis was performed to evaluate the effect of  
factors that may potentially influence the treatment and recurrence  rate. The 
following factors did not significantly affect the recurrence rate: patient age , sex , 
underlying cirrhosis , tumor pathology (primary versus metastasis) , size of the tumor 
(_3 versus _3 cm; , number of tumors ablated, approach of ablation, sub capsular 
location. 
        
 At univariate analysis  size of the tumor (>3cm)(p=0.02),number of tumors more 
than 3  (P = 0.04) and tumor proximity to major vessel. (P = 0.04)were significantly 
associated with recurrence. On follow up after two years seven patients were died 
which was significantly associated with recurrence (P = 0.05). Tumor pathology 
(Primary or secondary) (P = 0.94),sub capsular location, type of approach were not 
significantly associated with recurrence. Cirrhosis associated with high mortality (P = 
0.001) 
 TABLE 4. Treatment Outcomes  
Duration of ablation  16.7 min (6-88) 
Hospital stay (days)  7.3 +5.2 days (2-24) 
Complete ablation   18  78% 
Morbidity       7  30% 
Hospital mortality     1  4% 
Recurrence      14  61% 
Reablation                                 6          26% 
Overall Survival                       21 months (1-34) 
 
 
Discussion 
  
 The management of HCC and liver metastases is challenging.HCC and liver 
metastases from other solid tumors are major causes of morbidity and cancer-related 
death worldwide. Surgical resection provides the greatest potential for cure in patients 
with liver metastases or primary liver tumors.Unfortunately, many patients either have 
unresectable disease that is surgically inaccessible or have a large tumor burden or 
inadequate hepatic reserve Unfortunately, systemic chemotherapy is rarely effective 
and often associated with significant toxicity , with few complete responses and rare 
long-term progression-free survival, and usually do not significantly improve overall 
patient survival[22-24]. As previously noted, the majority of patients with primary or 
metastatic liver tumors are not candidates for resection; however, because potentially 
curative or palliative benefit may be derived from destruction of the liver tumors, in 
situ ablative techniques like PEI, cryoablation and RFA were developed. 
 
 RFA with other ablative modalities 
TABLE 5. Local Recurrence Rate: Univariate Analysis of Factors 
Factor Category % of No. of No. of  P 
Diameter (cm) <3cm 53 17 9  
 >3cm 83 6 5 p=0.02 
 Total 61 23 14  
      
No.Of  tumors <3 50 18 9  
 >3 100 5 5 p=0.04 
 Total 61 23 14  
      
Pathology HCC 58 12 7  
 CRLM 67 6 4  
 NELM 100 2 2 p=0.94 
 GIST 33 3 1  
 Total 61 23 14  
      
Proximity major vessel Yes 88 8 7  
 No 47 15 7 p=0.04 
 Total 61 23 14  
      
Location Subcapsular 67 9 6  
 Nonsubcapsular 57 14 8 p=0.31 
 Total 61 23 14  
      
Approach Percutaneous 64 11 7  
 Open 50 10 5 p=0.13 
 Laparoscopic 100 2 2  
 Total 61 23 14  
  
 RF thermal ablation has proved to be safe and effective for the treatment of 
hepatic tumors in patients who are considered to be unsuitable for surgical 
intervention and recently has attracted much attention. It has some merits compared 
with the other percutaneous techniques: The treatment time is shorter than that with 
the more popular percutaneous ethanol injection [25], the thermal lesions are larger 
than those obtained with a microwave electrode[26], and it is less expensive and easier 
to perform than interstitial laser photocoagulation, in which multiple fiber insertions 
are always required[27], and It is more safer and lower complications than 
cryotherapy[28]. 
 
HCC 
  
  HCC with cirrhosis responded best to treatment with RFA than liver 
metastases. Large lesions over 3 cm were treated showing lesion stability on CT scan 
and a dramatic fall in AFP levels. The reason for a good response in this group of 
tumors is probably due to the characteristic features of hepatocellular carcinomas, 
which offer better heat conduction. It is clear that RFA is a useful primary therapy in 
patients with unresectable HCC, especially in cases with a poor liver reserve from 
cirrhosis and with multiple and deep-sited lesions. Prior experience treating small 
HCC described the “oven effect” [25], whereby cirrhotic liver surrounding individual 
HCC nodules acts as a thermal insulator that increases tissue heating during RF 
therapy. 
 
  
 
Colorectal liver metastases 
  
 Colorectal liver metastases are usually hard. Patients with colorectal liver 
metastases usually have no cirrhosis, and as they have good liver reserve, most 
patients without extrahepatic spread are suitable for liver resection. Unresectability is 
commonly due to extensive multiple, bilateral disease or central lesions. Resection in 
combination with RFA in selected patients has been associated with a favorable long-
term survival. The application of RFA has a number of potential advantages in 
patients with otherwise unresectable liver malignancies. The procedure is relatively 
safe and well tolerated, and its complication rates in most series have been low.  
  
Importance of Local Recurrence 
  
 In the present study, a minimum follow-up of 6 months for each tumor and/or 
a mean follow-up of at least 12 months for the whole series were required for 
inclusion. A local recurrence seriously jeopardizes the chances of cure, as re-treatment 
is often impossible or has a high risk of failure. In an exhaustive review of 153 reports 
on RFC up until January 1, 2004, found only 18 authors (12%) who reported an 
attempt at local re-treatment. In total, of 64 recurrent tumors, only 35 (55%) were re-
treated and a complete coagulation was obtained in only 23 cases (36%). One report 
described 64 patients with local recurrences, of which only 34 received re-treatment.  
  
 For example, in a series of 364 hepatocellular carcinomas (HCC) smaller than 
3.5 cm,( 29) percutaneous session achieved a complete coagulation at immediate post-
RFC CT in 77% of tumors. Immediately after the second session in the incompletely 
treated cases, 99.7% of tumors appeared completely coagulated on CT.(34)Local 
recurrence rate after RFC of liver tumors varies widely between 2%1 and 68%.(30) The 
local recurrence rate in the present study was 60%. After re ablation recurrence rate 
was 35%.  
 
Tumor-Dependent Factors 
Number of Tumors 
    
 What counts for a patient, however, is the patient-based local recurrence rate. 
The more tumors a patient has, the more he is at risk for having at least one local 
recurrence. The deleterious effect of every factor that increases local recurrencerate on 
a single tumor level is being amplified in patients with multiple tumors. In this present 
study more than 3 number of tumors associated with high recurrence rate (p=0.04) 
 
Size 
 Nearly all authors agree that size is an important factor determining local 
recurrencerate,Several factors may contribute to the higher local recurrence rate for 
larger tumors. First, the fact that the size of individual RFC lesions is limited. A single 
coagulation may be sufficient to cover a small tumor and its 1-cm safety margin at 
both sides, but not to cover a large tumor. Unfortunately, when more than one 
treatment session is needed to obtain a complete coagulation, a higher risk of local 
recurrence has been described.(31)Our study also shows higher recurrence rate when 
the tumor size is more than 3cm(p=0.04) For large tumors, a large number of precisely 
calculated overlapping coagulations is necessary.  
 
 The technique of overlap is not easy: using ultrasound, it is difficult to visualize 
the tumor after the first coagulation session due to the appearance of a 
hyperechogenic microbubble cloud(33 ). As a result, nests of viable tumor cells will 
remain in the clefts between the incompletely fused coagulation zones. As an 
alternative to overlapping coagulations, new electrodes that claim to produce larger 
coagulation zones in a single session have been introduced recently. (35) A second 
factor is that larger tumors more frequently have irregular borders than small tumors. 
This is true for colorectal metastases, as well as for HCC. (36) If the coagulation is 
restricted to the main tumor without safety margin, spiky irregular extensions and 
satellites will be left untreated. 
 
Pathology 
  
 The impact of pathology on local recurrence rate is unclear in the literature(32). 
Local recurrence rates for HCC and colorectal metastases were similar.Differences in 
local recurrence rate between various tumor types may be due to differences in the 
mean natural growth rate. Present study did not show any significant differences in 
recurrence and outcome in relation to tumor type. 
 
Proximity of Large Vessels 
  
 The literature is not clear about the influence of the proximity of large vessels 
on the risk of local recurrence.Residual or recurrent tumor near large vessels was 
reported(37), and 3 comparative studies found an increased risk,  This  study, 
however, clearly confirms the impact of the proximity of large vessels on the risk of 
local recurrence.(p=0.04) 
 
Subcapsular Location 
  
 A subcapsular location was found to significantly increase local recurrence rate 
First, it is possible that in the percutaneous approach, subcapsular tumors have been 
undertreated for fear of burning adjacent organs, diaphragm, or the abdominal wall. 
Second, a percutaneous treatment of subcapsular tumors under local anesthesia with 
or without sedation can be painful, which may have prevented a correct complete 
coagulation. Subcapsular location did not show significant higher recurrence rate in 
this study. In conclusion, a subcapsular location is probably not a risk factor for local 
recurrence per se, but only if RFC is performed percutaneously. For this reason, as 
well as for the increased risk of bleeding and seeding when treated percutaneously, a 
laparoscopic or open approach is favored for subcapsular tumors (28). 
 
Physician-Dependent Factors 
Approach 
 RFC was pioneered by interventional radiologists. When RFC was first 
introduced clinically, it was entirely experimental and considered as a palliative 
treatment.In that context, the percutaneous route was justified as it was the least 
invasive and a less costly approach. Even today, the majority of RFC procedures are 
still performed percutaneously.In  one meta-analysis(21), a surgical approach 
(laparotomy or laparoscopy) clearly yielded statistically significantly (p = 0.001) 
superior results than a percutaneous approach,.Meta-analysis indicates that RFC by 
laparoscopy or laparotomy results in superior local control, independent of tumor size. 
In this study percutaneous approach was used in 48% of patients and open approach 
in 43% of cases.There is no significant difference in recurrence rate or outcome in 
relation to type of approach. 
 
Morbidity 
  
 RFA is currently receiving the greatest attention, given its general availability 
and the recent technical advances facilitating its use and effectiveness. From the vast 
experience, reasonable safety of the procedure has been established, with mortality 
and morbidity in the largest series at 0.2% and 1.7%, respectively(39). The overall 
morbidity in this series is 22%, which is higher than in other published series. We 
believe the higher morbidity in this series reflects the aggressive treatment approach 
we have adopted. 
 Survival 
  
 After Overall 5-year survival rates for patients who undergo hepatic 
cryoablation for metastatic colorectal carcinoma is 20% to 25%, and for HCC,25% to 
30%, in larger series.28-32 Thus, tumor ablation appears to positively affect long-term 
survival in these patient groups. Results of long-term follow-up have now been 
presented, with an overall survival of 93%, 62%, and 41% observed at 12, 24, and 36 
months, respectively(40). 
 
Adequate ablation of hepatic tumors is feasible using RF energy. Percutaneous, 
laparoscopic, and open surgical approaches can be used to deliver RF probes to 
hepatic tumors.The long-term survival data for this technology are still being gathered. 
In the present series overall survival rates for the hepatocellular carcinoma group (N = 
6) were 66%, 42%, at 1, and 2 years respectively. For the metastasis group (N = 9), the 
overall survival rates were 90%, 64%, at 1, and 2 years respectively 
 
 
 
 
 
 
Conclusion  
  In our experience, local recurrences were evident at a median follow-up time of 
6 months and were associated with ablation of larger and multiple tumors.  
          
 Additionally, based on our limited experience, repeat RFA seems to be well 
tolerated. However, recurrence in the liver is frequently accompanied by extrahepatic 
disease, and careful preoperative staging is essential to select patients who could 
potentially benefit from repeat RFA.  
         
 Resection or ablation of liver tumors will not cure most patients with primary or 
metastatic malignant disease, although long-term disease-free survival rates of 20 % 
to 40 %   
        
 For patients with resectable CRLM whom are appropriate candidates to undergo 
resection (medical condition and comorbidities) resection remains the gold standard. 
Complete ablation with superior local control by RFA is achievable for lesions up to 3 
cm in size.  
        
 Treatment with multimodality strategy is superior to single modality treatment 
for unresectable patients. Overall morbidity is related to patient selection and 
underlying co morbidities. We are very encouraged by our initial experience with RFA 
as a treatment for malignant liver tumors because it is safe, well tolerated, associated 
with few complications, and usually effective in controlling grossly or 
ultrasonographically evident in liver tumors.                                                                                      
 
 RFA for liver tumors should not be viewed as a simple technique but rather a 
specialized treatment modality that should be undertaken only by clinicians with 
adequate knowledge and experience in interventional therapies for liver tumors. 
          
  When initiating the treatment, a team approach with close collaboration 
between surgeons and interventional radiologists may shorten the learning curve. 
           
  Currently, many centers are reporting their initial experience with RFA for liver 
tumors. With adequate experience, RFA can be used to ablate liver tumors with low 
morbidity, low mortality, and a high complete ablation rate 
 
     .  
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 Table 1   -- Studies evaluating RFA alone for HCC 
 
Authors Year No. of patients Approach 
Tumor size 
(cm) 
Follow-up 
(mo) 
Local 
recurrence 
New liver or 
extrahepatic 
metastasis 
Overall 
survival 
Lencioni et al 2005 206 Perc Mean < 5 24 ± 21 10% 49% Median: 57
1y: 97% 
2y: 71% 
Guglielmi et al 2003 65 Perc Mean: 4 mean: 18 6.8% 28.3% 1y: 87% 
2y: 63% 
Buscarini et al 2001 88 Perc Mean: 3.5 mean: 34 CE: 29% 
 
N/A Median: 48
1y: 89% 
Giovannini et al 2003 56 Perc Mean: 4.1 mean: 14 7.1% 12.4% 3y: 94.2% 
Shibata et al 2006 74 Perc < 3 24 ICE 3y: 20% 
 
N/A  3y: 94% 
Raut et al 2005 194 Perc: 140 
Open: 54 
Median: 3.3 34.8 4.6% 48.5% 1y: 84.5% 
 
Berber et al 2004 66 Lap N/A N/A N/A N/A 1y: 78% 
2y: 48% 
Tateishi et al 2004 664 Perc Mean: 2.6 19 2.4% 54% 1y: 94.7% 
 
Poon et al 2004 80 
 
Perc  Median: 3.4
 
Median: 13 Sub: 4.3% 
 
Sub: 31.9% 
 
 1y: 88.3%
 
RFA = radiofrequency ablation; HCC = hepatocellular carcinoma; Perc = 
percutaneous; Lap = laparoscopic; N/A = not available; ICE = internally 
cooled electrode; EE = expandable electrode; Sub = subcapsular tumor; No 
Sub = without subcapsular tumor; Tx = treatment. 
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Table 2   -- Studies evaluating RFA versus other ablative therapies 
for HCC 
 
Authors Year No. of patients 
Appro 
ach Treatments 
Tumor 
size (cm) 
Follow-up 
(mo) 
Local 
recurrence 
New liver or 
extrahepatic 
metastasis 
Overa
surviv
Lin et al 2004 187 Perc RFA (62) 
PEI (62) 
PAI (63) 
Mean: 3 Mean: 35 RFA 3y: 14% 
PEI 3y: 34% 
PAI 3y: 31% 
RFA 3y: 45% 
PEI 3y: 48% 
PAI 3y: 46% 
RFA 3
PEI 3y
PAI 3y
Authors Year No. of patients 
Appro 
ach Treatments 
Tumor 
size (cm) 
Follow-up 
(mo) 
Local 
recurrence 
New liver or 
extrahepatic 
metastasis 
Overa
surviv
Lin et al 2004 157 Perc RFA (52) 
PEI (52) 
PEI HD (53) 
Mean: 3 Mean: 23.5 RFA 14% 
PEI 35% 
PEI HD 24% 
RFA 31% 
PEI 37% 
PEI HD 32% 
RFA 3
PEI 3y
 
Shiina et al 2005 232 Perc RFA (118) 
PEI (114) 
Mean: 3 Mean: 37.2 RFA 1.7% 
PEI 11.4% 
RFA 65% 
PEI 68% 
RFA 4
PEI 4y
Omata et 
al 
2004 1238 Perc RFA (629) 
MWA (85) 
PEI (524) 
RFA: 2.8 
MWA: 2.9
PEI: 2.9 
N/A N/A N/A RFA 3
77.8%
PEI 3y
Chen et al 2005 86 Perc RFA  (45) 
RF+PEI (41)
Mean < 5 N/A RFA 2y: 43% 
RFA+PEI: 26% 
N/A RFA 2
RF+PE
2y:73%
Lu et al 2005 102 Perc MWA (49) 
RFA (53) 
Mean < 2.5 Mean: 25.1 MWA: 11.8% 
RFA: 20.9% 
MWA: 69% 
RFA: 75% 
MW 3y
RFA 3
 
RFA = radiofrequency ablation; HCC = hepatocellular carcinoma; PEI = percutaneous ethanol 
injection; PAI = percutaneous acetic acid injection; MWA = microwave ablation; HD = high 
dose; N/A = not available. 
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 Table 3   -- Studies evaluating RFA versus resection in HCC 
 
Authors Year No. of patients Approach
Tumor 
size (cm) 
Follow-up 
(mo) 
Local 
recurrence 
New liver or 
extrahepatic 
metastasis 
Overall 
survival Com
Chen et al 2005 112 Perc <5 36 Resec. 25% 
RFA 24% 
N/A Rese 3y: 67%
RFA 3y: 65% 
N/A
Montorsi et 
al 
2005 98 Lap. <5 RFA 28 
Resec.22 
RFA 53% 
Resec.30% 
N/A RFA 4y: 45%
Resec.4y: 61%
N/A
Vivarelli et 
al 
2004 158 Perc >,<3 RFA 16 
Resec. 29 
N/A N/A RFA 3y: 33%
Resec.3y: 65%
RF
Re
Cho et al 2005 160 Perc/Open <5 36 Resec. 10% 
RFA 18% 
Resec. 33% 
RFA 28% 
Resec 3y: 80%
RFA3y:77% 
N/A
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RFA = radiofrequency ablation; HCC = hepatocellular carcinoma; Perc = percutaneous; Resec. = 
resection; N/A = not available. 
 Table 4   -- Studies evaluating RFA as a single therapy for CRLM 
 
Authors Year No. of patients Approach 
Tumor size 
(cm) 
Follow-up 
(mo) 
Local 
recurrence 
per tumor 
New liver or 
extrahepatic 
metastasis 
Overall 
survival
Curley et al 1999 123 
(crlm:61) 
Perc: 31 
Open: 92 
 3.4 
 
15 2% 28% 1y: N/A
De Baere et al 2000 68 
(crlm:58) 
Perc: 47 
Open: 21 
1-4.2 13.7 9% 15% 1y: N/A
Guilliams et al 2001 69 Perc: All   1-8.0 27 N/A 58% 1y: 90%
2y: 60%
4y: 22%
Guilliams et al 2005 73 Perc: All 3.9 
 
N/A N/A 50% Median: 
1y: 91%
5yr: 25%
Solbiati et al 2001 117 Perc: All : 2.6 
 
6-52 39% 57% Median: 
1y: 93%
3y: 46%
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RFA = radiofrequency ablation; Perc. = percutaneous; CRLM = colorectal liver metastasis; N/A 
= not available. 
  
 
 
 
 
 
 
 
 
Table 6   -- Studies evaluating RFA plus other therapies 
 
Authors Year No. of patients Approach
Tumor 
size (cm) 
Follow-up 
(mo) 
Local 
recurrence per 
tumor 
New liver or 
extrahepatic 
metastasis 
Overall
Cheng et al 2003 45 Lap: All N/A 11.5 N/A N/A RFA 7
RFA+H
HAIP 5
Scafie et al 2003 50 Open: All 0.5-8.5 20 4% 30% Median
Machi et al 2006 100 Open/Lap 1.1-4.2 24.5 6.7% 87% Median
5y: 30.
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 Table 5   -- Studies evaluating RFA plus resection for CRLM 
 
Authors Year No. of patients Approach Tumor size (cm) 
Follow-
up (mo)
Local 
recurrence per 
patient 
New liver or 
extrahepatic 
metastasis 
Over
survi
Pawlik et al 2003 172 (crlm:124) Open: All Median: 1.8
 
22 8% 52% Medi
Abdalla et al 2004 418 (3 groups) 
RFA: 57 
RFA+Resec: 158 
Resection: 190 
Open: All Median: 2.5 21 RFA 9% 
RFA+Resec.5%
RFA 40% 
RFA+Resec. 
37% 
RFA 
RFA
4y: 3
Elias et al 2005 63 Open: All N/A 28 7% 71.4% Medi
1y: 9
3y: 4
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CRLM = colorectal liver metastasis; RFA = radiofrequency ablation; Resec. = resection; N/A = 
not available. 
  
 
 
USG guided Percutaneous Radio 
frequency ablation being performed 
under general aneasthesia  
 
  
 
 
 
 
Figure 1. Radiofreqency ablation (RFA) of a large hepatocellular carcinoma. A, Preprocedural computed 
tomographic (CT) scan. B, A CT scan 2 months after RFA. 
 
 
 
Figure 2. (A) Pretreatment CT scan in a patient with two large 
liver metastases (arrows) from colorectal cancer. (B) CT scan 1 
month after resection of the left lobe lesion and RFA of the 
right lobe tumor. There is complete necrosis of the large right 
lobe lesion (open arrows) 
 
  
 Approach for radio frequency ablation (%) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Demography  
Tumour pathology  
  Master chart.  Characteristics of Patients who underwent   Radiofrequency 
Ablation 
ender 
Tumor 
pathology 
Cirrh
osis 
Previous 
hepatic 
resectio
n 
No. of 
tumor
s 
Size 
 (cm) 
No.of.RFA 
Sessions 
Proximit
y major 
vessel 
Sub 
capsular 
Location 
Per 
cutaneous 
Open 
Laparo 
scopic 
Complicatio
ns 
Recur 
rence 
Foll
 Tt 
male HCC yes no 1 6 3 yes no no yes no no yes rec 
male HCC no yes 1 2 1 no no yes no no no no 
male HCC yes no 1 7 2 yes no yes no no no yes 
male CRLM no no 1 1.5 2 no no no yes no no no 
male GIST no yes 1 1.5 1 no no yes no no yes yes rec 
male HCC no yes 1 3 2 no yes no yes no no yes rec 
male CRLM no no 2 3.5 2 no no yes no no no yes 
su
male HCC yes Yes 2 2 1 no no no yes no no no 
male HCC no yes 2 2 1 yes no yes no no no no 
male HCC yes no 2 4 1 no yes no yes no no no 
male GIST no no 2 1.5 3 no no no yes no no no 
male GIST no no 2 3 2 no yes no yes no no no 
male HCC yes no 2 5 2 yes no no yes no no yes 
male HCC yes no 3 3 2 no yes yes no no yes yes rec 
male NELM no yes 3 2.5 2 no yes yes no no no yes rec 
male CRLM no no 3 3 1 no no yes no no no no 
male NELM no no 3 2 2 no yes no no yes no yes rec 
male HCC yes yes 3 2 2 yes no yes no no yes yes rec 
male HCC yes no 3 2.5 3 no yes yes no no no no 
male CRLM no yes 3 2 2 no yes no yes no yes yes rec 
male CRLM no no 4 3 2 yes yes no no yes no yes rec 
male CRLM no yes 4 4 2 yes no yes no no yes yes rec 
male HCC no no 4 3 3 yes no no yes no no yes rec 
 
HCC-hepatocellular carcinoma, CRLM-colorectal liver metastasis, NELM-
neuroendocrine liver metastasis, 
GIST-gastrointestinal liver tumors,RFA-radiofrequecy ablation 
 
